BiotechTube

Pasireotide (SOM230)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Tumors

Conditions

Carcinoid Tumors

Trial Timeline

Jan 1, 2004 → Jul 1, 2008

NCT ID
NCT00088595

About Pasireotide (SOM230)

Pasireotide (SOM230) is a phase 2 stage product being developed by Novartis for Carcinoid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00088595. Target conditions include Carcinoid Tumors.

What happened to similar drugs?

1 of 9 similar drugs in Carcinoid Tumors were approved

Approved (1) Terminated (1) Active (7)
✅lanreotide (Autogel formulation)IpsenApproved
🔄Pasireotide + OctreotideNovartisPhase 3
🔄Octreotide + Placebo + EverolimusNovartisPhase 3
❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
🔄Lanreotide + PlaceboIpsenPhase 3
🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00994110Phase 3Completed
NCT00088595Phase 2Completed

Competing Products

20 competing products in Carcinoid Tumors

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
35
PasireotideNovartisPhase 1
29
Pasireotide + OctreotideNovartisPhase 3
40
Octreotide + Placebo + EverolimusNovartisPhase 3
40
LutatheraNovartisPhase 2
27
EPO906 epothilone BNovartisPhase 2
35
PanitumumabAmgenPhase 2
27
AxitinibPfizerPhase 2
35
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
31
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
29
lanreotide (Autogel formulation)IpsenApproved
40
Lanreotide + PlaceboIpsenPhase 3
37
BIM 23A760IpsenPhase 2
24
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
32
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
44
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
34
Telotristat etiprateLexicon PharmaceuticalsPhase 3
34
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
23